Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials.

Archer DF, Merkatz RB, Bahamondes L, Westhoff CL, Darney P, Apter D, Jensen JT, Brache V, Nelson AL, Banks E, Bártfai G, Portman DJ, Plagianos M, Dart C, Kumar N, Creasy GW, Sitruk-Ware R, Blithe DL.

Lancet Glob Health. 2019 Aug;7(8):e1054-e1064. doi: 10.1016/S2214-109X(19)30265-7. Epub 2019 Jun 20.

2.

Interventions for the prevention of pain associated with the placement of intrauterine contraceptives: An updated review.

Gemzell-Danielsson K, Jensen JT, Monteiro I, Peers T, Rodriguez M, Di Spiezio Sardo A, Bahamondes L.

Acta Obstet Gynecol Scand. 2019 May 21. doi: 10.1111/aogs.13662. [Epub ahead of print] Review.

PMID:
31112295
3.

Modern contraceptives in sub-Saharan African countries.

Bahamondes L, Peloggia A.

Lancet Glob Health. 2019 Jul;7(7):e819-e820. doi: 10.1016/S2214-109X(19)30199-8. Epub 2019 May 17. No abstract available.

4.

Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system.

Rebelo RC, Pignaton E, Valeria Bahamondes M, Costallat LTL, Appenzeller S, Bahamondes L, Fernandes A.

Arch Gynecol Obstet. 2019 Jun;299(6):1597-1605. doi: 10.1007/s00404-019-05131-x. Epub 2019 Apr 2.

PMID:
30941559
5.

Sexual Function and Quality of Life in a Cohort of Brazilian Users of Two Kind of Intrauterine Contraceptives.

Ferreira JM, Carreiro AV, Fernandes A, Bahamondes L.

Rev Bras Ginecol Obstet. 2019 Apr;41(4):236-241. doi: 10.1055/s-0039-1683370. Epub 2019 Mar 25.

6.

Follow-up visits to check strings after intrauterine contraceptive placement cannot predict or prevent future expulsion.

Bahamondes L, Monteiro I, Fernandes A, Gaffield ME.

Eur J Contracept Reprod Health Care. 2019 Apr;24(2):97-101. doi: 10.1080/13625187.2019.1586872. Epub 2019 Mar 14.

PMID:
30870042
7.

A single post-ovulatory dose of ulipristal acetate impairs post-fertilization events in mice.

Gómez-Elías MD, May M, Munuce MJ, Bahamondes L, Cuasnicú PS, Cohen DJ.

Mol Hum Reprod. 2019 May 1;25(5):257-264. doi: 10.1093/molehr/gaz013.

PMID:
30824928
8.

Thyroid function during the first year of use of the injectable contraceptive depot medroxyprogesterone acetate.

Quintino-Moro A, Zantut-Wittmann DE, Silva Dos Santos PN, Melhado-Kimura V, da Silva CA, Bahamondes L, Fernandes A.

Eur J Contracept Reprod Health Care. 2019 Apr;24(2):102-108. doi: 10.1080/13625187.2018.1559284. Epub 2019 Feb 5.

PMID:
30721635
9.

Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.

Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L.

Fertil Steril. 2018 Nov;110(6):1129-1136. doi: 10.1016/j.fertnstert.2018.07.003.

PMID:
30396557
10.

Assessment of biomarkers in women with endometriosis-associated pain using the ENG contraceptive implant or the 52 mg LNG-IUS: a non-inferiority randomised clinical trial.

Margatho D, Mota Carvalho N, Eloy L, Bahamondes L.

Eur J Contracept Reprod Health Care. 2018 Oct;23(5):344-350. doi: 10.1080/13625187.2018.1531117. Epub 2018 Oct 29.

PMID:
30372645
11.

Long term social consequences of adolescent pregnancy.

Bahamondes L.

BJOG. 2019 Feb;126(3):368. doi: 10.1111/1471-0528.15488. Epub 2018 Nov 5. No abstract available.

PMID:
30291658
12.

Advances in contraceptive vaginal rings: what does the future hold?

Monteiro I, Guazzelli CF, Bahamondes L.

Expert Opin Pharmacother. 2018 Oct;19(15):1685-1691. doi: 10.1080/14656566.2018.1519549. Epub 2018 Oct 5. Review.

PMID:
30286682
13.

Zika virus exposure in pregnancy and its association with newborn visual anomalies and hearing loss.

Peloggia A, Ali M, Nanda K, Bahamondes L.

Int J Gynaecol Obstet. 2018 Dec;143(3):277-281. doi: 10.1002/ijgo.12663. Epub 2018 Sep 24. Review.

PMID:
30191558
14.

A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.

Bahamondes L, Brache V, Ali M, Habib N; WHO study group on contraceptive implants for women.

Contraception. 2018 Sep;98(3):181-187. doi: 10.1016/j.contraception.2018.05.009. Epub 2018 May 16.

PMID:
29777663
15.

A case series on the use of levonorgestrel 52 mg intrauterine system after organ transplant.

Juliato CRT, Stahlschmidt P, Fernandes A, Monteiro I, Bahamondes L.

Contraception. 2018 Sep;98(3):252-254. doi: 10.1016/j.contraception.2018.04.017. Epub 2018 May 7.

PMID:
29746814
16.

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review.

Silva P, Qadir S, Fernandes A, Bahamondes L, Peipert JF.

Braz J Med Biol Res. 2018;51(6):e7575. doi: 10.1590/1414-431x20187575. Epub 2018 Apr 23. Review.

17.

Subclinical cardiovascular disease parameters after one year in new users of depot medroxyprogesterone acetate compared to copper-IUD.

Cursino K, de Lima GA, de Nazaré Silva Dos Santos P, Pavin EJ, Bahamondes L, Fernandes A.

Eur J Contracept Reprod Health Care. 2018 Jun;23(3):201-206. doi: 10.1080/13625187.2018.1455087. Epub 2018 Apr 19.

PMID:
29671344
18.

Hyperinsulinemic-euglycemic clamp over the first year of use of depot-medroxyprogesterone acetate as a contraceptive.

Melhado-Kimura V, Batista GA, de Souza AL, Silva Dos Santos PN, Alegre SM, Pavin EJ, Bahamondes L, Fernandes A.

Contraception. 2018 Apr 14. pii: S0010-7824(18)30139-2. doi: 10.1016/j.contraception.2018.04.003. [Epub ahead of print]

PMID:
29665358
19.

The use of long-acting reversible contraceptives in Latin America and the Caribbean: current landscape and recommendations.

Bahamondes L, Villarroel C, Frías Guzmán N, Oizerovich S, Velázquez-Ramírez N, Monteiro I.

Hum Reprod Open. 2018 Jan 23;2018(1):hox030. doi: 10.1093/hropen/hox030. eCollection 2018.

20.

Extended Effectiveness of the Etonogestrel-Releasing Contraceptive Implant and the 20 µg Levonorgestrel-Releasing Intrauterine System for 2 Years Beyond U.S. Food and Drug Administration Product Labeling.

Ali M, Bahamondes L, Bent Landoulsi S.

Glob Health Sci Pract. 2017 Dec 28;5(4):534-539. doi: 10.9745/GHSP-D-17-00296. Print 2017 Dec 28. No abstract available.

21.

Stagnant contraceptive sales after the Zika epidemic in Brazil.

Bahamondes L, Ali M, Monteiro I, Fernandes A.

Eur J Contracept Reprod Health Care. 2017 Oct;22(5):381-383. doi: 10.1080/13625187.2017.1397623. Epub 2017 Nov 23.

PMID:
29166843
22.

Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: A chart review of 776 women in Brazil.

Bahamondes L, Fernandes A, Bahamondes MV, Juliato CT, Ali M, Monteiro I.

Contraception. 2018 Mar;97(3):205-209. doi: 10.1016/j.contraception.2017.10.007. Epub 2017 Oct 18.

PMID:
29055780
23.

Sperm chemorepulsion, a supplementary mechanism to regulate fertilization.

Guidobaldi HA, Cubilla M, Moreno A, Molino MV, Bahamondes L, Giojalas LC.

Hum Reprod. 2017 Aug 1;32(8):1560-1573. doi: 10.1093/humrep/dex232.

PMID:
28854585
24.

Relationship between user satisfaction with the levonorgestrel-releasing intrauterine system and bleeding patterns.

Carvalho NM, Chou V, Modesto W, Margatho D, Garcia EAL, Bahamondes L.

J Obstet Gynaecol Res. 2017 Nov;43(11):1732-1737. doi: 10.1111/jog.13441. Epub 2017 Aug 17.

PMID:
28833891
25.

Barriers to Implementing and Consolidating a Family Planning Program that would meet Brazilian Needs.

Bahamondes L, Fernandes A, Monteiro I.

Rev Bras Ginecol Obstet. 2017 Aug;39(8):373-375. doi: 10.1055/s-0037-1604423. Epub 2017 Aug 3. No abstract available.

26.

Effect of the injectable contraceptive depot-medroxyprogesterone acetate on coagulation parameters in new users.

Melhado-Kimura V, Bizzacchi JMA, Quaino SKP, Montalvao S, Bahamondes L, Fernandes A.

J Obstet Gynaecol Res. 2017 Jun;43(6):1054-1060. doi: 10.1111/jog.13306. Epub 2017 May 15.

PMID:
28503774
27.

Estimated disability-adjusted life years averted by free-of-charge provision of the levonorgestrel-releasing intrauterine system over a 9-year period in Brazil.

Ferreira JM, Monteiro I, Fernandes A, Bahamondes MV, Pitoli A, Bahamondes L.

J Fam Plann Reprod Health Care. 2017 Jul;43(3):181-185. doi: 10.1136/jfprhc-2016-101569. Epub 2017 Mar 22.

28.

Study of the effect of ulipristal acetate on human sperm ability to interact with tubal tissue and cumulus-oocyte-complexes.

Zumoffen C, Gómez-Elías MD, Caille AM, Bahamondes L, Cuasnicú PS, Cohen DJ, Munuce MJ.

Contraception. 2017 Jun;95(6):586-591. doi: 10.1016/j.contraception.2017.02.019. Epub 2017 Feb 24.

PMID:
28238840
29.

Comments on manuscript: vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective cesarean section: a randomized double-blind clinical trial.

Bahamondes L, Monteiro I.

Contraception. 2017 Apr;95(4):434-435. doi: 10.1016/j.contraception.2017.01.012. Epub 2017 Feb 7. No abstract available.

PMID:
28189667
30.

Contraceptive sales in the setting of the Zika virus epidemic.

Bahamondes L, Ali M, Monteiro I, Fernandes A.

Hum Reprod. 2017 Jan;32(1):88-93. Epub 2016 Dec 7.

31.

The Practice of Hatha Yoga for the Treatment of Pain Associated with Endometriosis.

Gonçalves AV, Barros NF, Bahamondes L.

J Altern Complement Med. 2017 Jan;23(1):45-52. doi: 10.1089/acm.2015.0343. Epub 2016 Nov 21.

PMID:
27869485
32.

Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate.

Silva Dos Santos PN, de Souza AL, Batista GA, Melhado-Kimura V, de Lima GA, Bahamondes L, Fernandes A.

Arch Gynecol Obstet. 2016 Nov;294(6):1331-1336. Epub 2016 Sep 7.

PMID:
27604241
33.

Advantages of self-administration of injectable contraceptives.

Bahamondes L.

BJOG. 2017 Jan;124(2):209. doi: 10.1111/1471-0528.14301. Epub 2016 Oct 3. No abstract available.

34.

Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.

Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, Hubacher D; WHO study group on subdermal contraceptive implants for women.

Hum Reprod. 2016 Nov;31(11):2491-2498. Epub 2016 Sep 26.

35.

Knowledge of Latin American Obstetricians and Gynecologists regarding Heavy Menstrual Bleeding.

Bahamondes L, Marin V, Ciarmatori S, Silva-Filho AL, Acuña JM, Makuch MY.

Obstet Gynecol Int. 2016;2016:6870679. doi: 10.1155/2016/6870679. Epub 2016 Aug 25.

36.

A Qualitative Study on the Practice of Yoga for Women with Pain-Associated Endometriosis.

Gonçalves AV, Makuch MY, Setubal MS, Barros NF, Bahamondes L.

J Altern Complement Med. 2016 Dec;22(12):977-982. Epub 2016 Aug 23.

PMID:
27552065
37.

Comparison of two strategies for the administration of injectable depot medroxyprogesterone acetate: among women who returned to a family planning clinic at three- or six-month intervals.

Ferreira JM, Bottura BF, Gonçalves MP, Monteiro I, Bahamondes L.

Eur J Contracept Reprod Health Care. 2016 Oct;21(5):408-11. doi: 10.1080/13625187.2016.1217326. Epub 2016 Aug 17.

PMID:
27530899
38.

Sexual dysfunction risk and quality of life among women with a history of sexual abuse.

Carreiro AV, Micelli LP, Sousa MH, Bahamondes L, Fernandes A.

Int J Gynaecol Obstet. 2016 Sep;134(3):260-3. doi: 10.1016/j.ijgo.2016.01.024. Epub 2016 May 25.

PMID:
27350228
39.

Assessment of the quality of cervical mucus among users of the levonorgestrel-releasing intrauterine system at different times of use.

Moraes LG, Marchi NM, Pitoli AC, Hidalgo MM, Silveira C, Modesto W, Bahamondes L.

Eur J Contracept Reprod Health Care. 2016 Aug;21(4):318-22. doi: 10.1080/13625187.2016.1193139. Epub 2016 Jun 7.

PMID:
27269613
40.

Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.

Ragazini CS, Bahamondes MV, Prandini TR, Brito MB, Amaral E, Bahamondes L, Duarte G, Quintana SM, Ferriani RA, Vieira CS.

Eur J Contracept Reprod Health Care. 2016 Aug;21(4):285-9. doi: 10.1080/13625187.2016.1177718. Epub 2016 May 26.

PMID:
27227739
41.

The Use of Long Acting Reversible Contraceptives and the Relationship between Discontinuation Rates due to Menopause and to Female and Male Sterilizations.

Ferreira JM, Monteiro I, Castro S, Villarroel M, Silveira C, Bahamondes L.

Rev Bras Ginecol Obstet. 2016 May;38(5):210-7. doi: 10.1055/s-0036-1583758. Epub 2016 May 17.

42.

A prospective, open-label, single arm, multicentre study to evaluate efficacy, safety and acceptability of pericoital oral contraception using levonorgestrel 1.5 mg.

Festin MP, Bahamondes L, Nguyen TM, Habib N, Thamkhantho M, Singh K, Gosavi A, Bartfai G, Bito T, Bahamondes MV, Kapp N.

Hum Reprod. 2016 Mar;31(3):530-40. doi: 10.1093/humrep/dev341. Epub 2016 Jan 31.

43.

Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.

Simonatto P, Bahamondes MV, Fernandes A, Silveira C, Bahamondes L.

J Obstet Gynaecol Res. 2016 May;42(5):554-9. doi: 10.1111/jog.12939. Epub 2016 Jan 28.

PMID:
26817571
44.

Anemia should not be the reason for consideration of heavy menstrual bleeding.

Montalti CS, Castro S, Souza-Pereira M, de Souza Medina S, Bahamondes L, Monteiro I.

Int J Clin Pract. 2015 Dec;69(12):1526-7. doi: 10.1111/ijcp.12711. No abstract available.

PMID:
26647011
45.

In vitro and in vivo effects of ulipristal acetate on fertilization and early embryo development in mice.

Gómez-Elías MD, Munuce MJ, Bahamondes L, Cuasnicú PS, Cohen DJ.

Hum Reprod. 2016 Jan;31(1):53-9. doi: 10.1093/humrep/dev287. Epub 2015 Nov 17.

PMID:
26582845
46.

A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.

Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S; WHO Study Group on Contraceptive Implants for Women.

Hum Reprod. 2015 Nov;30(11):2527-38. doi: 10.1093/humrep/dev221. Epub 2015 Sep 25.

PMID:
26409014
47.

Knowledge and attitudes of Latin American obstetricians and gynecologists regarding intrauterine contraceptives.

Bahamondes L, Makuch MY, Monteiro I, Marin V, Lynen R.

Int J Womens Health. 2015 Jul 16;7:717-22. doi: 10.2147/IJWH.S84173. eCollection 2015.

48.

Insulin resistance parameters in users of the injectable contraceptive depot medroxyprogesterone acetate during one year of use.

Cursino K, Sider M, Pavin EJ, dos Santos Pde N, Bahamondes L, Zantut-Wittmann DE, Fernandes A.

Eur J Contracept Reprod Health Care. 2016;21(1):22-9. doi: 10.3109/13625187.2015.1059415. Epub 2015 Jul 3.

PMID:
26140543
49.

Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.

Modesto W, Bahamondes MV, Bahamondes L.

J Womens Health (Larchmt). 2015 Aug;24(8):636-40. doi: 10.1089/jwh.2014.5077. Epub 2015 Jun 22.

PMID:
26098552
50.

Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.

Modesto W, Dal Ava N, Monteiro I, Bahamondes L.

Arch Gynecol Obstet. 2015 Dec;292(6):1387-91. doi: 10.1007/s00404-015-3784-0. Epub 2015 Jun 19.

PMID:
26088190

Supplemental Content

Loading ...
Support Center